SCM
SYRE icon

Sterling Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Sterling Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3K Sell
262
-789
-75% -$57.6K ﹤0.01% 1819
2026
Q1 		$53K Sell
1,051
-559
-35% -$21.1K ﹤0.01% 1613
2025
Q4 		$52.7K Buy
1,610
+396
+33% +$10.3K ﹤0.01% 1782
2025
Q3 		$20.3K Buy
1,214
+690
+132% +$11.3K ﹤0.01% 2130
2025
Q2 		$7.84K Sell
524
-105
-17% -$1.55K ﹤0.01% 2278
2025
Q1 		$10.1K Sell
629
-380
-38% -$7.91K ﹤0.01% 1858
2024
Q4 		$23.5K Buy
1,009
+894
+777% +$26.2K ﹤0.01% 1822
2024
Q3 		$3.38K Buy
+115
New +$3.2K ﹤0.01% 1932

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Sterling Capital Management's SYRE Position: Q2 2026 in Review

Sterling Capital Management reduced its Spyre Therapeutics (SYRE) stake by 75% in Q2 2026, selling an estimated $57.6K and leaving 262 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1819.

Sterling Capital Management first reported a position in SYRE in Q3 2024 and has held it in 8 quarters since. The position peaked at $53K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Sterling Capital Management held 262 shares of Spyre Therapeutics worth $23.3K as of Q2 2026.
  • Sterling Capital Management sold 789 Spyre Therapeutics shares in Q2 2026, an estimated $57.6K.
  • Spyre Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1819 holding.
  • Sterling Capital Management first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Spyre Therapeutics position peaked at $53K in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.